Expression and production of tenascin in benign and malignant lesions of melanocyte lineage.
The distribution of the extracellular matrix (ECM) glyco-protein tenascin (TN) has been evaluated immunohistochemically in benign and malignant lesions of the melanocytic lineage. Results of our study show that TN is detectable in a variety of benign and malignant lesions. In primary melanomas, TN displays a heterogeneous distribution, and a higher degree of expression of this glycoprotein is seen in lesions of greater dermal invasiveness. TN expression does not correlate with that of other ECM glycoproteins such as fibronectin. In vivo and in vitro experiments have also demonstrated that melanoma cells are capable of producing and releasing TN in the extracellular milieu.
Regina Elena Cancer Institute, Rome, Italy.
P G
PG
Natali
M R
MR
Nicotra
A
A
Bartolazzi
M
M
Mottolese
N
N
Coscia
A
A
Bigotti
L
L
Zardi
D000911:Antibodies, Monoclonal; D015816:Cell Adhesion Molecules, Neuronal / Q000096:biosynthesis*; D004591:Electrophoresis, Polyacrylamide Gel; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis*; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D006801:Humans; D007124:Immunoenzyme Techniques; D007911:Lentigo / Q000378:metabolism; D008544:Melanocytes / Q000378:metabolism*; D008545:Melanoma / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009506:Nevus / Q000378:metabolism*; D019063:Tenascin; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D009363:Neoplasm Proteins; D019063:Tenascin